The global Healthcare industry continues to advance with innovative therapies for chronic kidney disease (CKD), positioning the Daprodustat Market as a rapidly growing segment within renal care. According to Future Market Insights (FMI), the global Daprodustat Market is projected to grow from USD 407.16 million in 2026 to USD 953.48 million by 2036, registering a robust 8.9% CAGR during the forecast period. Growing adoption of oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), expanding access to renal anemia treatment programs, increasing prevalence of chronic kidney disease, and rising demand for high-quality active pharmaceutical ingredients (APIs) are expected to fuel sustained market expansion worldwide.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-33615

The market is expected to generate an absolute dollar opportunity of USD 546.32 million between 2026 and 2036. Growing commercialization of oral renal anemia therapies, increasing regulatory approvals, expanding dialysis care programs, and greater emphasis on traceable pharmaceutical supply chains continue to strengthen long-term market demand.

Key Daprodustat Market Highlights at a Glance

·         Market Size (2026): USD 407.16 Million

·         Forecast Market Size (2036): USD 953.48 Million

·         Forecast Period: 2026–2036

·         CAGR (2026–2036): 8.9%

·         Absolute Dollar Opportunity: USD 546.32 Million

·         Leading Sales Channel: Direct Supply (69.0% Market Share in 2026)

·         Leading Form: Powder (62.4% Market Share in 2026)

·         Fastest-growing Country: China (10.6% CAGR through 2036)

·         Key Segments Covered: Form, Purity Grade, Application, Sales Channel, Buyer Type, Region

·         Report Pages: 250

·         Last Updated: June 30, 2026

·         Reviewed by: Anurag Sharma

Why Is the Daprodustat Market Growing?

The market is expanding steadily as healthcare providers increasingly adopt oral HIF-PHI therapies for managing renal anemia associated with chronic kidney disease.

Key Growth Drivers

• Rising prevalence of chronic kidney disease worldwide.
• Increasing adoption of oral HIF-PHI therapies for renal anemia.
• Growing dialysis patient population requiring anemia management.
• Expansion of regulated pharmaceutical manufacturing.
• Rising demand for high-purity pharmaceutical APIs.
• Strengthening regulatory compliance and quality documentation.
• Increasing healthcare investments in nephrology care.
• Growing focus on reliable pharmaceutical supply chains.

As CKD management programs continue expanding globally, demand for innovative oral therapies such as daprodustat is expected to remain strong.

👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-33615

According to Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights, "Daprodustat is emerging as a strategically important API market where regulatory readiness, manufacturing consistency, and supply transparency increasingly influence supplier selection. Growing adoption of oral renal anemia therapies is expected to create long-term commercial opportunities for qualified pharmaceutical manufacturers."

Which Sales Channel Leads the Daprodustat Market?

Direct Supply remains the dominant sales channel, accounting for 69.0% of global market revenue in 2026.

Pharmaceutical manufacturers increasingly prefer direct procurement models that ensure quality agreements, regulatory documentation, supply continuity, and comprehensive audit support.

Sales Channel Highlights

• Direct Supply dominates overall market demand.
• Regulatory documentation strengthens supplier qualification.
• Long-term procurement agreements improve supply stability.
• Audit-ready manufacturing supports commercial partnerships.

Why Does Powder Form Dominate the Market?

Powder formulations account for 62.4% of the global market in 2026 owing to their compatibility with oral tablet manufacturing, blending efficiency, and formulation flexibility.

Manufacturers continue prioritizing powder APIs to support scalable commercial production while maintaining stringent quality standards.

Form Segment Highlights

• Powder remains the preferred formulation.
• Supports efficient oral solid dosage manufacturing.
• Enables scalable pharmaceutical production.
• Improves formulation consistency and quality control.

👉 Explore the Latest Pharmaceutical Industry Analysis Now:
https://www.futuremarketinsights.com/industry-analysis/pharmaceuticals

How Are Pharmaceutical Manufacturing Trends Supporting Market Expansion?

Growing emphasis on regulatory compliance, impurity control, and reliable API production is driving investment across the pharmaceutical manufacturing ecosystem.

Manufacturing Highlights

• High-purity APIs improve regulatory compliance.
• Traceable production systems strengthen buyer confidence.
• Reliable supply chains support long-term procurement.
• Advanced quality management enhances commercial competitiveness.

Market Dynamics

Market Drivers

Growing prevalence of chronic kidney disease, increasing demand for oral renal anemia therapies, expansion of dialysis treatment programs, rising pharmaceutical manufacturing standards, and improving regulatory support continue driving market growth.

Market Restraints

Stringent regulatory approval requirements, pricing pressures, complex API manufacturing processes, patent-related competition, and evolving quality compliance standards continue posing challenges.

Market Trends

Innovation continues reshaping the renal therapeutics landscape.

Major trends include:

• Expansion of oral HIF-PHI therapies.
• Increasing investment in API manufacturing.
• Growing focus on impurity control.
• Rising adoption of audit-ready quality systems.
• Strengthening pharmaceutical supply chain transparency.
• Expansion of commercial procurement partnerships.

Regional and Country Outlook

Asia continues to lead global market expansion owing to rising chronic kidney disease prevalence, increasing HIF-PHI adoption, and expanding pharmaceutical manufacturing capabilities.

China is projected to be the fastest-growing country, registering a 10.6% CAGR through 2036, supported by growing CKD treatment demand, expanding regulatory approvals, and increasing investment in pharmaceutical production.

Japan is expected to maintain strong growth driven by established renal anemia treatment practices and continued adoption of oral HIF-PHI therapies.

North America and Europe continue to provide significant commercial opportunities owing to advanced healthcare infrastructure, robust regulatory frameworks, and increasing focus on innovative nephrology treatments.

Competitive Landscape

Competition remains moderately consolidated, with leading companies focusing on regulatory compliance, high-quality API manufacturing, commercial supply agreements, manufacturing expansion, and strategic partnerships to strengthen their global market positions.

Key Companies

• GSK
• Kyowa Kirin
• MSN Laboratories
• Hetero Drugs
• MetroChem API
• Laurus Labs
• Aurobindo Pharma
• WuXi STA
• CordenPharma
• Seqens

👉 Read Full Report:
https://www.futuremarketinsights.com/reports/daprodustat-market

Frequently Asked Questions

1.       What is the projected size of the Daprodustat Market by 2036?

The global Daprodustat Market is projected to reach USD 953.48 million by 2036, growing from USD 407.16 million in 2026.

2.       What is the expected CAGR of the Daprodustat Market?

The market is forecast to expand at an 8.9% CAGR between 2026 and 2036.

3.       Which sales channel dominates the market?

Direct Supply leads the market, accounting for 69.0% of total revenue in 2026.

4.       Which form holds the largest market share?

Powder remains the leading form, capturing 62.4% of the market in 2026.

5.       What factors are driving market growth?

Growing prevalence of chronic kidney disease, rising adoption of oral HIF-PHI therapies, expanding dialysis programs, increasing demand for high-quality APIs, strengthening regulatory compliance, and improving pharmaceutical supply chain transparency continue driving global market growth.

Related Reports

·         Sleep Study Market - https://www.futuremarketinsights.com/reports/sleep-studies-market

·         Minimally Invasive Neurosurgery Devices Market - https://www.futuremarketinsights.com/reports/minimally-invasive-neurosurgery-devices-market

·         Image Guided Systems Market - https://www.futuremarketinsights.com/reports/image-guided-systems-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie® Award, and a member of the Greater New York Chamber of Commerce) provides deep insights into governing factors elevating demand in global markets.

FMI delivers market intelligence, consulting services, and syndicated research reports across healthcare, pharmaceuticals, chemicals, materials, food ingredients, industrial manufacturing, sustainability, and advanced materials sectors.

With global expertise and industry-focused research capabilities, FMI provides actionable insights that help organizations understand market dynamics and identify emerging opportunities.

Contact

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware 19713, USA

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.

Phone: +91 8600020075

For Media: Rahul.Singh@futuremarketinsights.com

Email: sales@futuremarketinsights.com

Website: www.futuremarketinsights.com